Intellia Therapeutics Inc... (NTLA)

NasdaqGM: NTLA · Real-Time Price · USD

12.72

-0.15 (-1.17%)

At close: Aug 31, 2026, 8:00 PM

12.84

+0.86%

After-hours: 5:59 PM

The price, the headline numbers and the latest news, in one place.

-1.17% (1D)

No data available

Bid	8.2
Market Cap	1.78B
Revenue (ttm)	59.51M
Net Income (ttm)	-399.98M
	1.79
	-3.34
	n/a
	-4.89
P/B (ttm)	2.45
P/S (ttm)	29.98
Earnings Date	Nov 5, 2026

Ask	13.92
Volume	1,450,253
Avg. Volume (20D)	4,816,612
Open	12.69
Previous Close	12.87
Day's Range	12.44 - 12.77
52-Week Range	7.95 - 28.25
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About NTLA

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product c...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 6, 2016

Employees 377

Stock Exchange NasdaqGM

Ticker Symbol NTLA

Website https://www.intelliatx.com

Full Company Profile

Financial Performance

In 2025, Intellia Therapeutics's revenue was 67.67M, an increase of 16.92% compared to the previous year's 57.88M. Earnings were -412.69M, a decrease of -20.49%.

Financial Statements

Earnings Surprise

Intellia Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $7.66M misses estimates by $0, with -46.23% YoY decline.
EPS of -0.8 misses estimates by -0.02, with 18.37% YoY growth.

Next Earnings Release

Intellia Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · Zacks

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

1 week ago · 24/7 Wall St.

Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly load...